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Abstract: Psoriasis is a relatively common, chronic and disabling skin disease, with an 
immune-related pathogenesis and a genetic background which may be triggered by several 
environmental factors including smoking and infections. There is no cure but several treat-
ment options are available. The treatment of psoriasis is far from being satisfactory due to 
impractical modalities of topical treatment and suboptimal safety profile of the systemic 
treatments available. In the last few years, parallel to an improved understanding of the 
disease pathogenesis, there has been a boost in research on new agents for the treatment 
of psoriasis. Ustekinumab, a monoclonal antibody targeting the p40 subunit of interleukin 
(IL)-12 and IL-23, is one such new agent. Psoriasis and its management are briefly reviewed 
before focusing on the evidence for ustekinumab in the treatment of chronic plaque psoriasis 
through a systematic search of the main registries of ongoing trials up to December 2009. 
Ustekinumab proved to be very effective short term in the control of clinical manifestations 
in psoriasis compared with placebo and with etanercept. Long-term and comparative data 
are still limited. There is a need for continuing research on the long-term effectiveness and 
safety of the drug.
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Psoriasis is a chronic relapsing skin disease characterized, in the most usual form, 
namely chronic plaque psoriasis, by well demarcated erythematous and scaling 
plaques especially located on the extensory body areas and the scalp. The disease 
deeply affects well being and has emotional and relational consequences which go 
far beyond the skin.1 In addition, a link has been repeatedly suggested between the 
inflammatory process sustaining psoriasis and metabolic derangements.2 A number 
of diseases have been associated with psoriasis; in particular, arthritic manifesta-
tions in so-called psoriatic arthritis.3 A holistic approach, including education and 
psychological support, is needed for an optimal care of psoriatic patients. The main 
aim of the treatment is to reduce the burden of the disease over time, controlling 
symptoms, helping patients to cope with the chronic nature of the disease, limiting 
psychological and relational consequences, and preventing systemic complica-
tions and co-morbidity. Psoriasis is a disorder with a relatively high prevalence 
in the general population mainly as a result of its chronicity and the absence of 
a cure. Incidence rates are estimated to vary from 50 to 140 new cases per 100,000 
people per year. Point prevalence estimates vary between 0.8% and 4% in different 
countries.4Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Psoriasis as a complex disorder
Severity grading
Agreement exists on the management value of distinguishing 
between nonpustular and pustular varieties. Among non-
pulstular varieties, guttate and chronic plaque psoriasis can be 
considered, while both localized and generalized varieties of 
pustular psoriasis can be identified. A further distinction can 
be made between stable and transitional varieties, ie, unstable 
inflammatory psoriasis and erythroderma. Most of the clini-
cal research on psoriasis has been restricted to chronic plaque 
psoriasis. The evidence for other clinical varieties is very 
limited. If not otherwise specified, we will make reference in 
the following discussion to chronic plaque psoriasis. At vari-
ance with many chronic disorders, psoriasis does not appear 
to progress steadily toward a definite outcome and hence it 
is difficult to split the disease into stages by natural history. 
Attempts at measuring disease severity have been largely lim-
ited to assessing the skin area involved with psoriatic lesions 
at a point in time and related clinical issues like the degree 
of scaling and infiltration. The prototype for such measures 
is the Psoriasis Area and Severity Index (PASI), which was 
developed as an outcome measure in clinical trials on oral 
retinoids in 1978. These indexes do not make any difference 
between different pattern distributions or clinical subgroups 
and are poorly suited to assess disease varieties other than 
chronic plaque psoriasis.5 Since psoriasis is a chronic disease, 
one crucial issue would be to assess it over a relevant time 
frame and not only at a point in time. In the long term, simple 
outcome measures applicable in all patients seem preferable. 
These may include clinical remission, number of hospital 
admissions or ambulatory consultations, and major disease 
flare-ups. A number of quality of life instruments have been 
designed to asses dermatologic conditions or, more specifi-
cally, psoriasis. The most popular ones are the Dermatology 
Life Quality Index (DLQI), the Psoriasis Disability Index 
(PSI), and the Psoriasis Life Stress Inventory (PLSI).6
A useful distinction should be made between severe psoriasis 
and psoriasis that severely affects quality of life. As pointed 
out recently, such a distinction has relevant consequences in 
terms of disease management.7 Patients with objectively mild 
psoriasis experiencing a disproportionate impact on quality of 
life may benefit from psychological support and learning coping 
strategies, rather than systemic drugs to suppress disease activ-
ity. Recently, a set of criteria were developed by the European 
Medicines Agency (EMEA) mainly for the purpose of stan-
dardizing assessment in randomized clinical trials. The system 
distinguishes mild psoriasis (,10% body surface area involved 
and manageable by topical agents) from moderate-severe and 
severe psoriasis (skin involvement is .10% and .20%, respec-
tively), for which systemic treatment is needed.8
Co-morbidities in psoriasis
There is evidence that the clinical impact of psoriasis is 
not limited to the skin. Arthritis is an established associa-
tion of psoriasis. Psoriatic arthritis has been defined as an 
inflammatory arthritis occurring during the course of pso-
riasis and characterized by negative rheumatoid factor.3 In 
spite of the fact that psoriatic arthritis represents in clinical 
series a proportion as high as 25% of all psoriasis patients, 
population-based estimates suggest that no more than 4% to 
5% of psoriatic patients presents seronegative arthritis as an 
associated feature.9
Psoriasis at its first clinical diagnosis has been associated 
with smoking and increased body mass index,10–12 and it is not 
surprising that established psoriasis has been associated with 
cardiovascular disease.13 Whether psoriasis is per se a risk 
factor for cardiovascular disease is still an open question.
Besides cardiovascular disease, a number of other condi-
tions, most of which are also associated with smoking or obe-
sity, have been linked with psoriasis, including   inflammatory 
bowel disorders and tumors of specific sites, eg, lung can-
cer, colonic cancer, and kidney cancer.4 Not surprisingly, 
  psoriasis has been also associated with depression.14
Psoriasis causation
While the exact cause remains unknown, it is clear that 
both genetic and environmental factors play a role (mul-
tifactorial inheritance). It has been estimated that the risk 
for a child to develop psoriasis is about 40% if both parents 
are affected and 15% if one parent or 6% if one sibling is 
affected. PSORS1 is the main psoriasis susceptibility gene 
which has been mapped in the major histocompatibility 
complex (MHC),15 a finding consistent with the notion that 
the pathogenesis of psoriasis involves antigen recognition 
by epidermal CD8+ T lymphocytes. Current genome-wide 
association studies using gene chips and adopting a case-
control design instead of linkage analysis are fostering our 
understanding of genetic influences on psoriasis and confirm 
that psoriasis is a polygenic disorder to which relatively 
frequent alleles may contribute. Among the several genetic 
loci associated with psoriasis in case-control studies are 
IL12B, IL23R, IL23A.16,17   Observational studies have linked 
the onset of psoriasis with physical trauma, acute infection, 
some medications (eg, lithium salts and beta-blockers), 
stressful life events, cigarette smoking and increased body 
mass index.10–12Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Pathogenetic models: relevance  
of Th1 and Th17 responses
The hallmark features of a psoriatic plaque include 
  hyperproliferation of epidermal keratinocytes with   resulting 
hyperkeratosis, infiltration of lymphocytes, and   angiogenesis. 
Mitotic activity of basal keratinocytes is increased   several-fold 
in psoriatic skin, so that keratinocytes need only 3 to 5 days in 
order to move from basal layer to cornified layer instead of the 
normal 28 to 30 days. This dramatically shortened maturation 
time is accompanied by altered differentiation, reflected by 
the focal absence of the granular layer of the epidermis and 
parakeratosis, ie, presence of nuclei in the thickened cornified 
layer. The incompletely differentiated keratinocytes release 
few of the extracellular lipids used commonly in the adhesion 
of the keratinocytes, resulting in a poorly adherent stratum 
corneum. This is the basis for the formation of the classic 
silvery scale in the psoriatic lesions. What factors prompt 
localized hyperproliferation of keratinocytes and hyperkera-
tosis is still imprecisely understood. With the serendipitous 
discovery of the utility of cyclosporin in the treatment of 
psoriasis in 1979, the role of the immune system in triggering 
psoriasis has been increasingly emphasized. A vicious cycle 
of continuous T cell and dendritic cell (DC) activation can 
be envisioned within the chronic psoriatic plaque. During 
T-cell activation, the cytokine milieu determines the char-
acteristics of the emerging effector T cells. In psoriasis, a 
so-called Th1 response seems to dominate, characterized by 
secretion, among others, of interferon (IFN)-γ, tumor necrosis 
factor (TNF)-α, and interleukin (IL)-2. A more recent role for 
Th17 cells, independent of activation from IFN-γ, has been 
also proposed18 with an interplay between IFN-γ-producing 
Th1 cells and IL-17-producing T-cells in psoriatic lesions.19
A number of recent excellent reviews, to which the 
reader is addressed, thoroughly discuss current pathogenetic 
models.20,21
iL-12, iL-23 and Th17
IL-23 p19 was discovered in 2000.22 It had no biological activ-
ity, but when combined with the IL-12p40 subunit of IL-12 
formed a novel heterodimeric cytokine named IL-23. IL-23 
was found to be expressed by several activated human cells like 
monocytes, macrophages, DCs, T cells, B cells and endothelial 
cells.22,23 IL-23 binds to its heterodimeric receptor complex 
composed of the IL-12Rβ1 and IL-23R subunits.24 Whereas 
IL-12Rβ1 is also part of the IL-12 receptor, IL-23R is unique 
to the IL-23 receptor complex (Figure 1). The IL-12Rβ1 and 
Figure 1 Schematic representation of interleukin (iL)-12 and iL-23 with their receptors.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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IL-23R chain are associated with intracellular proteins of the 
Janus kinase (Jak) family to induce downstream signaling, 
resulting in a sequence of phosphorylation processes activat-
ing signal transducer and activator of transcription (STAT) 
molecules, namely STAT1, STAT3, STAT4, and STAT5, 
which translocate into the nucleus where they bind DNA in 
the promoter region of target genes.24
IL-23, rather than IL-12, appears to be the critical   molecule 
for the development of autoimmune disease. Expression of 
IL-23p19 in lesional tissue in psoriasis,25 Crohn’s disease26 
and rheumatoid arthritis27 support this possible role.
While IL-12 causes CD4+ T-cell differentiation to IFN-γ 
producing Th1 cells, IL-23 promotes the expansion of the 
Th17 population. In addition to IL-17A, these cells have been 
shown to produce IL-17F, IL-22 and IL-26, as well as IL-6, 
IL-21, TNF-α -and IFN- γ.28 To date, IL-17A, IL-17F and 
IL-26 are considered to be specific Th17 cytokines, whereas 
the others, can be produced also by Th1 cells.28 Functional 
studies of Th17 cytokines has revealed an important and 
unique role for these cytokines in host protection against 
infections with extracellular pathogens such as Gram-  negative 
bacteria and Candida albicans.29 A number of autoimmune 
disorders have been associated with overproduction of Th17 
cytokines and interference with their production attenuate 
autoimmune diseases. Interestingly, intradermal injection 
of IL-23 in mice led to erythema, induration and promi-
nent dermal papillary blood vessels with   histopathological 
  features resembling psoriasis.30 IL-17 producing cells have 
been isolated from the dermis of psoriatic lesions.31 A key 
cytokine produced by Th17 cells is IL-22. IL-22 has a pecu-
liar activity in immune innate response, and its role in the 
pathogenesis of psoriasis has been documented.32
Existing therapeutic options  
for psoriasis
The management of a chronic skin disorder like psoriasis is 
a multi-step process in which different phases can be identi-
fied. In particular, a clearance phase, which involves a more 
intensive treatment approach with the aim of clearing existing 
psoriasis lesions, and a maintenance phase, with the main aim 
of preventing disease relapse, are usually considered.
Treatment options for psoriasis are traditionally classified 
as topical, those based on ultraviolet light, and systemic, the 
last including conventional and so-called biological agents 
or biologics.33 The term biologics has been challenged.34 
It refers to a heterogenous variety of antibodies and fusion 
proteins which directly target specific steps in the purported 
immunologic process of psoriasis. A classical approach to 
psoriasis treatment is stepwise, beginning with the least 
invasive and safest treatment, progressing to more potent, 
and potentially more risky, therapeutic options until suf-
ficient psoriasis plaque clearance and control are achieved. 
According to this approach, topical preparations are the 
preferred option for mild disease. It has been documented 
that compliance may be quite poor with topical agents and 
treatment may be cumbersome.35 Treatment of moderate to 
severe psoriasis is often initiated with phototherapy or photo-
chemotherapy. Phototherapy relies on ultraviolet B radiation 
(UVB) delivered as broadband, narrowband (restricted to 
the wavelength of 311 to 313 nm) or as high-energy 308 nm 
monochromatic light through excimer laser. Photochemo-
therapy involves the combination of ultraviolet A radiation 
with psoralens (PUVA). Conventional systemic therapies 
currently approved in various countries for the treatment 
of moderate to severe psoriasis include ciclosporin, metho-
trexate, and oral retinoid therapy. Other systemic therapies, 
such as hydroxyurea or fumaric acid esters, are approved 
in a small number of countries or may be used off-label for 
the treatment of psoriasis. A better understanding of the 
immune pathways critical to the pathogenesis of psoriasis 
has prompted the development of new targeted agents, the 
so-called biologics. The   biological agents available for 
  treating psoriasis may be classified into two main   categories: 
agents that modulate the   function of T lymphocytes by act-
ing on their receptors, namely   alefacept and efalizumab 
(withdrawn from the market in 2009 because of the increased 
risk of progressive   multifocal leukoencephalopathy), 
and cytokine-blocking agents. Before the introduction of 
IL-12/23 antagonists, the latter were limited to antagonists of 
TNF-α – etanercept, infliximab and adalimumab. Although 
biological treatments have been a significant advance in the 
management of   psoriasis, their exact place in the hierarchy 
of systemic therapies will not be known until controlled 
trials have compared them against each other and with tradi-
tional approaches. The long-term safety of biologics is also 
a concern. TNF-α is produced by a wide range of immune 
and non-immune cells and has broad inflammatory effects, 
upregulating both innate and adaptive immunity. The use of 
TNF-α antagonists has been associated with an increased 
risk of tuberculosis reactivation36 and herpes zoster,37 and 
with case reports of severe opportunistic infections.38 Con-
cerns have been also raised about an increased risk of solid 
tumors and lymphoma,39 but robust data are lacking. TNF-α 
antagonists can worsen pre-existing heart failure and should 
be avoided in severe congestive cardiac failure (New York 
Heart Association class III and IV).40 Cases of demyelinating Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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disease have been reported with TNF-α antagonists, and it is 
recommended that these agents are avoided in patients with 
a personal or first-degree family history of demyelinating 
disorder.41 The formation of autoantibodies and of antibodies 
against biologic drugs themselves is sometimes observed but 
the clinical relevance is not yet clear.42
Targeting IL-12 and IL-23  
in psoriasis: ustekinumab
As mentioned previously, IL-12 and IL-23 play key roles 
in the development of the immune response in psoriasis by 
inducing naive CD4+ lymphocytes to differentiate into Th1 
and Th17 cells, respectively. In light of the biologic evidence 
available, the drug ustekinumab (formerly called CNTO 
1275) was developed. This agent is a fully human IgG1 
monoclonal antibody that binds to the p40 subunit of IL-12 
and IL-23, and prevents their interaction with IL-12Rβ1 thus 
blocking the cascade of cytokines associated with receptor 
activation. Ustekinumab is administered by subcutaneous 
injections. It has been approved for use in psoriasis, in Canada 
(December 2008), the European Union (January 2009), and 
the US (September 2009).
In addition to ustekinumab, another IL-12/23p40 
  monoclonal antibody is in an advanced phase of   development, 
namely ABT-874. Finally, an oral IL-12/23 inhibitor has been 
tested in early clinical trials in Crohn’s disease.43
Pharmacokinetic studies
The pharmacokinetic properties of ustekinumab have been 
well characterized following single-dose subcutaneous 
administration (0.27 to 2.7 mg/kg) and single dose intra-
venous administration (0.1 to 5.0 mg/kg) in patients with 
psoriasis. The pharmacokinetics of ustekinumab were linear 
over the wide dose range studied. After a single subcutane-
ous injection, ustekinumab showed to be slowly absorbed 
into systemic circulation, with a mean Tmax of approximately 
12 days and then slowly eliminated from the circulation with 
a mean t1/2 of approximately 20 days. The mean t1/2, rang-
ing from 14.9 to 28.6 days and increasing with increasing 
doses.44
Population pharmacokinetic analyses have been also 
conducted based on data obtained from the large scale 
phase 3 studies PHOENIX 1 and PHOENIX 2, and with 
inclusion of serum concentration data from 1937 patients.45 
Several variables, including demographics, baseline disease 
characteristics, prior use of systemic therapies for psoriasis, 
immune response status, and comorbidities, were evaluated. 
In the analyses, body weight, diabetes, and development 
of antibodies to ustekinumab, were important covariates 
significantly affecting the apparent clearance and/or appar-
ent volume of distribution of ustekinumab. In particular, an 
approximately 55% higher apparent clearance value and 
37% higher volume of distribution was predicted for patients 
weighting more than 100 kg compared with those 100 kg or 
less. The mean steady state trough serum concentration with 
every 12-week dosing for patients weighing more than 100 kg 
was approximately 30% lower than for patients weighing 
100 kg or less. In patients with diabetes an approximately 
28.7% higher apparent clearance value and 13.2% higher vol-
ume of distribution was predicted by the model. A total of 62 
patients (3.2%) developed antibodies against ustekinumab. 
These patients had an apparent clearance 35.5% higher than 
patients not developing antibodies. Only the effect of body 
weight was considered as clinically relevant.
Drug-to-drug interaction
In the context of the population pharmacokinetic study 
  reference above, the potential effect on ustekinumab dis-
position of concomitant medications used by at least 5% of 
the study patients was assessed.46 None of the concomitant 
medications, including non-steroidal anti-inflammatory 
drugs (acetaminophen, ibuprofen, acetylsalicylic acid, and 
naproxen), oral hypoglycemic (metformin),   dyslipidemics 
(atorvastatin), diuretics (hydrochlorothiazide), thyroid 
  hormone (levothyroxine) and influenza vaccine, had a 
  significant effect on the apparent clearance of ustekinumab.
Pharmacodynamic studies
Based on the same patient group assessed in the   population 
pharmacokinetic studies mentioned above,   exposure-response 
studies were performed, using serum ustekinumab concentra-
tions, and reduction in PASI score as the response variable.47 
The placebo effect although minor was also integrated into 
the model. The serum ustekinumab concentration causing 
50% of the maximum effect (IC50) showed a striking differ-
ence between partial responders, achieving PASI 50 but not 
PASI 75 at 28 weeks, and responders achieving PASI 75 at 
28 weeks, the median IC50 value in partial responders being 
approximately 30-fold higher than in responders. These 
data suggest that partial responders were not as sensitive as 
the responders to ustekinumab and that these patients may 
require higher doses and/or more frequent administrations to 
attain comparable efficacy. None of the covariates evaluated, 
including demographics, baseline disease characteristics, 
and co-morbidities, significantly contributed to the between-
subject variability in the pharmacodynamic parameters.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Pre-clinical and early clinical studies  
of ustekinumab in psoriasis
Pre-clinical analyses in animal models have been con-
ducted with anti-IL-12/23p40, showing that the antibodies 
can decrease disease activity in mouse models of multiple 
sclerosis48 and Crohn’s disease.49 Anti-IL-12/23p40 also suc-
cessfully abolished psoriasis-like lesions in mice.50
In humans, results from two phase 1 studies documented 
that ustekinumab acts via modulation of type-1 chemokines 
and cytokines in lesional skin paralleled by a sustained 
clinical improvement following a single dose of the drug.44,51 
Interestingly, after a single-dose administration, baseline 
levels of TNF-α were significantly correlated with clini-
cal improvement at week 16, suggesting that the baseline 
levels of the cytokine may predict therapeutic response.52 
In addition, gene expression analyses of pre- and post-
treatment lesional skin indicate that the administration of 
anti-IL-12/23p40 rapidly by week 2, downregulates mRNA 
expression of type 1 cytokines, as well as IL-12/23p40 and 
IL-23p19. IL-12p35 was upregulated, although IL-12p35 
copy number was low and results were variable. The rapid 
decrease of IL-12/23p40 and IL-23p19 expression levels 
preceded clinical response and histological changes.
Randomized clinical trials of ustekinumab 
in chronic plaque psoriasis
Results from a total of four randomized clinical trials in chronic 
plaque psoriasis are available.53–56 These results are summa-
rized in Table 1. In three studies ustekinumab was compared 
against placebo while in a single trial an active comparator, 
ie, etanercept, was adopted. In all the randomized trials avail-
able, disease severity was judged by assessing the extent and 
clinical aspects of psoriatic lesions at baseline by using the 
PASI score. Patients were eligible if their PASI score was $12 
or surface area involved was $10%. Efficacy was primarily 
assessed by estimating the percentage of changes in the PASI 
score at 12 to 20 weeks compared with baseline (a variation 
of 75%, referred to as PASI 75, was considered as the main 
outcome). In spite of the use of placebo, no restriction in the 
eligibility criteria, based on the lack of previous response to 
other systemic agents, was made at entry. It should be noted 
that some complexities were added to the design of the studies 
with the combination of a first controlled study phase (main 
study phase) with a crossover phase where patients initially 
treated by placebo or etanercept were shifted to ustekinumab 
treatment (randomized to two different dosages in PHOENIX 
1 and 2), and with a third randomized withdrawal study phase 
where treatment was withdrawn, in a randomized fashion, in 
patients who achieved a significant improvement on usteki-
numab, and substituted by placebo (PHOENIX 1) or with an 
intensification phase where partial responders to ustekinumab 
were re-randomized to maintain their 12-week regimen or to 
escalate to dosing every 8 weeks (PHOENIX 2). The main 
problem originated by these sequential phases was that only 
a proportion of the patients initially randomized were actually 
evaluated in the subsequent phases.
Study NCT0032021653 is a phase II placebo-controlled 
trial involving 320 patients with moderate to severe plaque 
psoriasis. The main study phase lasted 20 weeks. The study 
design required patients in the ustekinumab group who did 
not respond (PGA $ 3) by week 16 to receive an additional 
dose, and those in the placebo group to receive a single dose of 
ustekinumab 90 mg at week 20. At week 12, 51.6% and 59.4% 
of patients who received ustekinumab 45 mg and 90 mg once 
weekly, respectively, and 67.2% and 81.3% who received 
four weekly 45-mg and 90-mg doses, respectively, achieved 
at least a 75% improvement from baseline in PASI (PASI 
75), compared with 1.6% of patients who received placebo 
(P , 0.001 each). Histological analyses were completed in the 
phase II study at baseline and week 12. Ustekinumab signifi-
cantly reduced the epidermal   thickness of lesional skin.
The PHOENIX 1 trial was designed as a phase III study 
of the efficacy and safety of ustekinumab 45 mg and 90 mg, 
administered subcutaneously.54 Participants were randomly 
assigned to receive ustekinumab 45 or 90 mg   subcutaneously 
at weeks 0 and 4 and then every 12 weeks, or placebo at 
weeks 0 and 4, with subsequent crossover to ustekinumab at 
week 12. In addition, patients who were initially randomized to 
receive ustekinumab at week 0 and who achieved a significant 
improvement were re-randomized at week 40 to observe any 
loss of response with either maintenance therapy or treatment 
withdrawal for a total trial duration of 76 weeks. At week 12, 
PASI 75, the primary end-point; was achieved by 171 (67⋅1%) 
patients receiving ustekinumab 45 mg, 170 (66⋅4%) receiv-
ing ustekinumab 90 mg, and eight (3⋅1%) receiving placebo 
(P , 0.0001 for all the differences). Data concerning improve-
ment of PASI of at least 90% (PASI 90) or of at least 50% 
(PASI 50), were consistent with those obtained for the primary 
end-point. Complete disappearance of psoriatic lesions (PASI 
100) was achieved by 32 (12.5%) patients receiving usteki-
numab 45 mg, 28 (10.9%)   receiving   ustekinumab 90 mg and 
none of the patients receiving   placebo. Clinical improvements 
were paralleled by improvements in the DLQI. At week 40, 
long-term response had been achieved by 150 patients in 
the 45 mg ustekinumab group and 172 patients in the 90 mg 
group. Of these, 162 patients were randomly assigned to Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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Table 1 Summary of clinical data from phase iii randomized trials of ustekinumab in chronic plaque psoriasis
Trial No. patients recruited Efficacy data Safety data
NCT00320216 320 PASi 75 at week 20 (primary end point):  
Ustekinumab:  
  45 mg once weekly: 52% 
  90 mg once weekly: 59%  
  45 mg 4 times weekly: 67% 
  90 mg 4 times weekly: 81% 
Placebo: 2%
Any adverse event:  
Ustekinumab: 68%–90% according to dosage 
Placebo: 72%  
Serious adverse events:  
Ustekinumab: 2%–5%, according to dosage  
 
Placebo: 1%
PHOeNiX1  766 PASi 75 at week 12 (primary end point): 
Ustekinumab (2 doses at weeks 0 and 4): 
  45 mg: 67.1%  
  90 mg: 66.4%  
Placebo: 3.1% 
PASi 50 at week 12  
Ustekinumab (2 doses at weeks 0 and 4): 
  45 mg: 83.5% 
  90 mg: 85.9% 
Placebo: 10.2% 
PASi 90 at week 12: 
Ustekinumab (2 doses at weeks 0 and 4): 
  45 mg: 41.6%  
  90 mg: 36.7% 
Placebo: 2.0%  
DLQia (% of patients with score 0 or 1) at week 12: 
Ustekinumab (2 doses at weeks 0 and 4): 
  45 mg: 53.1% 
  90 mg: 52.4% 
Placebo: 6.0%
Any adverse event:  
Ustekinumab: 57.6% and 51.4% of patients on 
45 mg and 90 mg, respectively 
Placebo: 48.2%  
(most common events: upper respiratory 
tract infection, arthralgia, and headache)  
Serious adverse events:  
Ustekinumab: 0.8% and 1.6% of patients on 
45 mg and 90 mg, respectively  
Placebo: 0.8%  
(most common serious  
events: infections)
PHOeNiX2  1230 PASi 75 at week 12 (primary end point) 
Ustekinumab (2 doses at weeks 0 and 4): 
  45 mg: 66.7%  
  90 mg: 75.7%  
Placebo: 3.7%  
PASi 50 at week 12  
Ustekinumab (2 doses at weeks 0 and 4):  
  45 mg: 83.6%  
  90 mg: 89.3% 
Placebo: 10%  
PASi 90 at week 12  
Ustekinumab (2 doses at weeks 0 and 4):  
  45 mg: 42.3%  
  90 mg: 50.9%  
Placebo: 0.7%  
DLQi (% of patients with score 0 or 1) 
at week 12 (*):  
Ustekinumab:  
  45 mg: 55.3%  
  90 mg: 56.4%  
Placebo: 3.2% 
Any adverse event:  
Ustekinumab: 53.1% and 47.9% of patients on 
45 mg and 90 mg, respectively  
Placebo: 49.8%  
(most common events: arthralgia, cough, 
headache, upper respiratory tract infection, 
and injection site erythema)  
Serious adverse events:  
Ustekinumab: 2.0% and  
1.2% of patients on 45 mg and 90 mg, 
respectively  
Placebo: 2.0%  
(most common serious events: infections) 
ACCePT 903 PASi 75 at week 12 (primary end point):  
Ustekinumab (2 doses at week 0 and 4):  
  45 mg: 67.5%  
  90 mg: 73.8%  
etanercept (50 mg twice weekly):  
  56.8%  
PASi 90 at week 12 
Ustekinumab (2 doses at weeks 0 and 4): 
  45 mg: 36.4%  
  90 mg: 44.7%  
etanercept (50 mg twice weekly):  
  23.1% 
Any adverse event:  
Ustekinumab: 66% and 69.2% of patients 
on 45 mg and 90 mg, respectively  
etanercept: 70%  
(most common events: upper respiratory tract  
infection, headache, back pain, injection-site 
reaction)  
Serious adverse events:  
Ustekinumab: 1.9% and 1.2% of patients on 
45 mg and 90 mg, respectively  
etanercept: 1.2%  
(most common serious events: infections) 
Abbreviation: PASi, psoriasis area and severity index.
aDLQi is a 10-item questionnaire that determines the extent of the effect of psoriasis on patient-reported quality of life, with overall scores ranging from 0 (“not at all”) to 
30 (“very much”).Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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maintenance ustekinumab and 160 to withdrawal. PASI 75 
response was better maintained to at least 1 year in those 
receiving maintenance ustekinumab than in those withdrawn 
from treatment at week 40.
The aim of the PHOENIX 2 phase III trial was to assess 
whether dosing intensification would increase the response to 
the treatment in partial responder patients (between PASI 50 
and PASI 75).55 Subjects were randomly assigned to receive 
ustekinumab 45 or 90 mg subcutaneously at weeks 0 and 4 
and then subsequently every 12 weeks, or to receive placebo 
at weeks 0 and 4, with subsequent crossover to the study drug 
at week 12. Partial responders among those originally ran-
domized to ustekinumab, were re-randomized at week 28 to 
receive the drug every 12 weeks or to increase dose adminis-
tration to every 8 weeks for a total trial duration of 52 weeks. 
At week 12, PASI 75, the primary end-point, was achieved 
by 273 (66.7%) patients receiving   ustekinumab 45 mg, 311 
(75⋅7%) receiving   ustekinumab 90 mg, and 15 (3⋅7%) receiv-
ing placebo. Complete clearance was achieved by 74 (18.1%) 
patients receiving ustekinumab 45 mg, 75 (18.2%) receiving 
ustekinumab 90 mg, and none of the patients receiving pla-
cebo. About 20% of the patients treated by ustekinumab were 
classified as partial   responders. In the group on ustekinumab 
90 mg, PASI 75 at week 52, was achieved by 22 (68.8%) out 
of 32 patients randomized to receive an intensified regimen 
with ustekinumab 90 mg every 8 weeks, and 11 (33.3%) out 
of 33 patients who continued to receive the same dose every 
12 weeks (P = 0.004). No similar improved response was 
observed with dose intensification in patients on ustekinumab 
45 mg. Partial responders appeared to represent a distinct 
subgroup of patients who had higher bodyweight, a longer 
duration of skin disease, a history of psoriatic arthritis and 
an overall greater resistance to biological agents compared 
with responders. Although this subpopulation had lower 
mean serum drug levels of ustekinumab than did patients 
who responded to treatment, lower serum concentrations of 
ustekinumab alone did not completely explain their partial 
response. The response to dose intensification in the 90 mg 
but not the 45 mg ustekinumab groups suggests that these 
patients may need for response a serum concentration of the 
drug four to five times higher compared with responders.
The ACCEPT trial was a 12-week trial comparing 
  ustekinumab 40 mg or 90 mg at week 0 and 4 with subcutane-
ous etanercept, 50 mg, twice-weekly for 12 weeks.56 Patients in 
the etanercept group who did not have a response (ie, patients 
classified as having moderate, marked, or severe psoriasis) 
at week 12 received 90 mg of ustekinumab at weeks 16 and 
20, and patients who did not have a response to ustekinumab 
received one additional dose of ustekinumab at week 16. 
  Treatment was interrupted starting at week 12 in all patients 
with cleared, minimal, or mild psoriasis. Patients were retreated 
with ustekinumab if psoriasis recurred and were followed up to 
week 44. At week 12, a total of 67.5% of patients who received 
45 mg of ustekinumab and 73.8% of patients who received 
90 mg of ustekinumab achieved PASI 75, as compared with 
56.8% of those who received high dose etanercept (P = 0.01 
and P , 0.001, respectively). At week 12, clearance was docu-
mented in 16.3% of patients on ustekinumab 45 mg, 26.2% 
on ustekinumab 90 mg, and 8.6% on etanercept (P = 0.006 
and P , 0.001, respectively). Among patients who did not 
respond to etanercept, 48.9% had at least 75% improvement 
in the PASI score and 23.4% had at least a 90% improvement 
after crossing over to 90 mg of ustekinumab for 12 weeks. The 
median time to recurrence was 14.4 weeks among patients who 
received 45 mg of ustekinumab, 18.1 weeks among those who 
received 90 mg of ustekinumab, and 7.3 weeks among those 
who received etanercept. Of the 633 patients who were treated 
with ustekinumab again after the recurrence of psoriasis, 534 
(84.4%) had a physician’s global assessment score of 0 to 2 
within 12 weeks after retreatment.
Ustekinumab has been also studied in psoriatic arthritis. 
A crossover, phase II study included 76 patients injected with 
this drug at weeks 0, 1, 2 and 3, who then received placebo 
injections at weeks 12 and 16. Seventy other patients received 
placebo at 0, 1, 2 and 3 weeks, followed by ustekinumab injec-
tions at weeks 12 and 16. At week 12, 42% of the treatment 
group achieved an ACR20 (20% improvement in symptoms 
according to the American College of Rheumatology criteria) 
compared with 14% of the placebo group. By the end of the 
36-week study period, 42% of the original placebo patients 
who had received injections of ustekinumab only at weeks 12 
and 16 achieved an ACR20 response.57 These results are prom-
ising, but further data possibly against an active comparator 
and on a longer term run are required in psoriatic arthritis.
Safety issues
The current understanding of the safety of ustekinumab in 
psoriasis is mainly derived from a total of 2266 patients 
treated in the context of controlled randomized trials and 
their subsequent open phase for up to 18 months.58 During 
the placebo-controlled phases of the trials, the rates and types 
of adverse events, as well as laboratory abnormalities, were 
similar among the patients receiving placebo and usteki-
numab (50.4% vs 54.6%, respectively). The incidence of 
serious infections with ustekinumab 45 mg and 90 mg was 1.2 
and 1.7 per 100 patient-years of follow-up, respectively, and Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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malignancies other than nonmelanoma skin cancer (NMSC), 
0.25 and 0.57 per 100 patient-years, respectively. These rates 
were comparable with placebo-treated patients. In spite of 
these reassuring data, long-term effects and safety profile 
remain in question as for any newly developed medication, 
and post-marketing data are still required for ustekinumab 
especially to assess the risk for rare but clinically relevant 
conditions and for events with a latency period (Table 2).
One concern is the potential carcinogenicity risk associ-
ated with ustekinumab, since rodent tumor models suggest that 
mouse IL-12 can promote antitumor effects and that IL-12/ 
23p40-deficient mice, or mice treated with anti-IL-12/23p40 
antibody, have decreased host defense to tumors and increased 
risk of ultraviolet-induced skin tumors.59 On the other hand, 
IL-23p19-deficient mice have a strong resistance to tumor 
challenge.60 The relevance of these findings for malignancy 
risk in humans treated by ustekinumab is unknown.
Another concern is a possible increased risk of   infections 
in patients treated with anti-IL-12/23p40 antibodies. Data 
from studies in deficient knockout mice or in mice   following 
very high doses of neutralizing antibody administration 
  suggest that IL-12 (Th1) and IL-23 (Th17) responses may 
contribute to protective immune responses to viral and bac-
terial pathogens.61,62 In contrast to observations in murine 
models, humans with genetic deficiencies in the Th1 and 
Th17 pathways, involving, among the others, IL-12/23p40, 
IL-12Rβ1, IFN-γ receptor 1 and 2, have normal resistance 
to viral or fungal infections63,64 but are susceptible to 
non-tuberculosis primary Mycobacterium and recurring 
Salmonella spp. infections. To date, no cases of typical or 
atypical mycobacterial or salmonella infections have been 
reported in clinical studies of ustekinumab. Reasons may be 
represented by screening for latent tuberculosis at baseline 
and treatment of positive cases, or by limited exposure to 
date in large endemic populations. It is also possible that 
ustekinumab treatment does not confer complete inhibition 
of IL-12/23p40, as is observed with genetic deficiencies.
Further data are also required to assess the effectiveness 
of ustekinumab compared with other more commonly used 
agents, and to explore the use of the drug in varieties of 
psoriasis other than chronic plaque. Psoriasis is associated 
with several co-morbidities, and one should consider whether 
aggressive management of psoriasis, especially with a sys-
temic agent such as ustekinumab, could change the course 
of these co-morbidities.
Because of concerns over potential long-term risks, the 
Food and Drug Administration is requiring a risk evaluation 
and mitigation strategy that include a 5-year follow-up of 
patients originally recruited into clinical trials, the enroll-
ment of newly treated patients in a registry that will follow 
them up for 8 years, and the establishment of a pregnancy 
registry. The Psoriasis Longitudinal   Assessment and Regstry 
  (PSOLAR) is a Centocor Ortho Biotech Inc. sponsored, 
voluntary registry, originally implemented for the post-
marketing evaluation of infliximab, which is now available 
in several countries to collect information on patients treated 
with ustekinumab and other systemic agents for psoriasis 
(http://clinicaltrials.gov/ct2/show/NCT00508547).
Treatment guidelines
Ustekinumab is administered by subcutaneous injection. 
For patients weighing ,100 kg, the dose is 45 mg initially 
and 4 weeks later, followed by 45 mg every 12 weeks. For 
patients weighing .100 kg, the recommended dose is 
90 mg initially and 4 weeks later, followed by 90 mg every 
12 weeks. In Europe, ustekinumab has been approved by 
the EMEA, as for other biological agents, for the treatment 
of severe plaque psoriasis in adults who fail to respond to 
or who have contraindications to, or are intolerant to other 
systemic agents, including cyclosporin, methotrexate, and 
PUVA. Similar criteria were adopted for registration in 
Canada, while in the US no restriction was made based on 
previous treatment response. As a consequence, patients 
exposed to ustekinumab in Europe and Canada are likely to 
be more complex than those enrolled in US and they need 
more strict monitoring.
Ustekinumab was not included in the recently delivered 
European S-3 guidelines for the treatment of psoriasis, 
because the deadline of the literature search was prior to 
the registration of ustekinumab.65 The guidelines of the 
Table 2 Main safety concerns in ustekinumab-treated patients
Safety issue Evidence available
Severe infections Humans with genetic deficiencies in 
iL-12/23p40, iL-12Rβ1, iFN-γ receptor 1 and 2,   
are especially susceptible to non- 
tuberculosis primary Mycobacterium and  
recurring Salmonella spp. infections
Malignancies IL-12/23p40-deficient mice have decreased  
host defense to tumors and increased risk  
of ultraviolet-induced skin tumors
Reversible posterior  
leukoencephalopathya
One case has been reported on  
ustekinumab treatment. it has been  
described in immune-suppressed patients
aA  syndrome  characterized  by  headache,  confusion,  seizures,  visual  loss.  it  has 
been associated with malignant hypertension, eclampsia and immune-suppressive 
treatment in the post-transplant setting. Symptoms usually abate with responsible 
drug dose reduction, or control of hypertension and electrolyte level.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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British Association of Dermatologists restrict the use to 
ustekinumab to patients who fulfil the EMEA registration 
criteria and where TNF antagonist therapy has failed or was 
contraindicated.66
Concluding remarks
Given the currently known characteristics of ustekinumab, 
the drug appears to be an effective, relatively safe and 
  convenient agent in treating psoriasis. However, wider expe-
rience is needed. Both pragmatic randomized clinical trials 
adopting an active comparator and formal cohort studies 
possibly nested within disease registries are needed to better 
define the activity profile of the drug and to better establish 
its role in the clinical management of psoriasis.
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